ClinicalTrials.gg
CompletedNCT05414994Updated Oct 21, 2026

Assessment of the Ocular Microbiome in Health and Disease

An observational study in Microbial Colonization, Eye Diseases and Ophthalmopathy, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Vanderbilt University Medical Center · Observational

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.

Enrollment
20th of 44
500 · median 350
Started
2023
with 14 others
Observational
45 of 161
15 open now
Registered
123rd of 161
by date
Lead sponsor
4 of 161
Vanderbilt University Medical Center

Among the 161 studies in Communicable Diseases with a site in United States, this one is the 20th largest by enrollment of the 44 observational ones that give a count, is one of 15 that started in 2023, is one of 45 observational ones, and was the 123rd registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Communicable Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a longitudinal analysis of the ocular microbiome in adults.

Read the detailed description

The microbiome is defined as a community of microbial organisms that reside in a specific host niche. There is a growing body of literature on the association between gut microbiome and disease entities such as inflammatory bowel disease, colon cancer and presumably an association that might influence response to treatment in some patients.

Recent data suggest the existence of a resident ocular microbiota that may play a protective role in corneal infections [1-4]. However, not much is known about the ocular microbiome and its association with disease or response to treatment. The National Eye Institute (NEI) recently hosted a symposium to discuss challenges to characterize the ocular microbiome and its role in promoting or preventing ocular diseases. One of the major challenges discussed is the lack of a normative population- based database describing the ocular microbiome.

In response the NEI as part of the Anterior segment initiative put out an RFA requesting proposals on methods of collection of biological samples and associated clinical data (e.g. demographic, residence, medications, allergies); processing of samples to extract analytes (e.g., DNA, RNA, protein, metabolites) and characterizing microorganisms in a low biomass niche, specifically the ocular surface using16S rRNA marker gene, whole metagenome sequencing (WMS), and metatranscriptomics approaches.

03

Conditions studied

  • Microbial Colonization
  • Eye Diseases
  • Ophthalmopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We anticipate there will be approximately 20% failure rate due to the low bacterial load in these samples and so we will have to collect more samples to account for the loss of data.

We estimate that 20 patients in each cohort of eyes with ocular disease - 100 total patients and 500 normal eyes will give us sufficient power to explore this topic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

We will include subjects who meet all of the following criteria:

  • 18 years of age or older
  • Provide
  • Cohort A - normal eyes with no ocular disease
  • Cohort B - primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months
  • Cohort C - non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)
  • Cohort D - Dry AMD (age related macular degeneration)
  • Cohort E - Wet AMD
  • Cohort F - diabetic retinopathy

Exclusion criteria

Exclusion Criteria:

We will exclude subjects who meet all of the following criteria:

  • Prior ocular disease either of the anterior or posterior segment
  • Any medical comorbidities except well controlled DH and HTN
  • Unable to follow up with study procedures as described
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
500 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A

    normal eyes with no ocular disease

    Other: Eye swab

  • Cohort B

    primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months

    Other: Eye swab

  • Cohort C

    non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)

    Other: Eye swab

  • Cohort D

    Dry AMD (age related macular degeneration)

    Other: Eye swab

  • Cohort E

    Wet AMD

    Other: Eye swab

  • Cohort F

    diabetic retinopathy, any stage

    Other: Eye swab

Interventions

  • OtherEye swab

    This is a simple swab under the eyelids of both eyes

06

What researchers measure

Primary outcomes

  1. Normal Ocular Microbiome

    Number of patients in middle Tennessee with a normal ocular microbiome by development of a normative database.

    Time frame: 3 years

Secondary outcomes

  1. Whole Metagenome Sequencing Methods

    Number of ocular microbial species in different age and ethnic groups by the development of whole metagenome sequencing methods optimized for low biomass samples to characterize the ocular surface (anterior segment) microbiome.

    Time frame: 3 years

Other outcomes

  1. Novel Metatranscriptomics Analysis

    Number of active microbial pathways and host epithelial gene expression profiles by novel metatranscriptomics analysis.

    Time frame: 3 years

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Sep 2026, 36 months.

Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's 36 months is close to that.

Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2027 → Sep 2026 and completion Dec 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
Jun 10, 2022
StartActual
Sep 7, 2023
Primary completionActual
Sep 30, 2026was Sep 2027
CompletionActual
Sep 30, 2026was Dec 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Primary completion
Sep 30, 2027→Sep 30, 2026 (actual)
Oct 21, 2026
Study completion
Dec 30, 2027→Sep 30, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2027→Sep 30, 2026 (now actual)
    Study completion Dec 30, 2027→Sep 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05414994
Responsible party
Sapna Gangaputra (Assistant Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Jun 10, 2022
Start date
Sep 7, 2023
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion